ABSTRACT
Solid organ transplant recipients (SOTRs) have an increased risk of malignancy, with skin cancer being the most common. Although immunotherapy has revolutionized the oncologic landscape for the treatment of advanced malignancies, its use in the transplant population remains controversial because of the risk of allograft rejection. SOTRs have largely been excluded from clinical trials involving cancer immunotherapy and as such, there is a paucity of data on the use of these agents in the transplant population. Herein, we highlight the current data surrounding the use of cancer immunotherapy in SOTRs, focusing on immune checkpoint inhibitors (ICIs) and the oncolytic virotherapy of talimogene laherparepvec (T-VEC).
